Scinai Ends PC111 Partnership, Pivots to NanoAb Platform and CDMO Growth
SCNI is trading near its 52-week low of $1.85 (1.1% below the low).
Summary
Scinai Immunotherapeutics announced the termination of its option and license agreements with PinCell S.r.l. for PC111, effective August 31, 2026, after failing to reach an extension. The company will redirect R&D resources to its NanoAb platform and CDMO business, citing capital preservation and the absence of secured grant funding for PC111. Management emphasized the decision was not based on negative scientific findings. The company is advancing two IL-17 programs under its NanoAb platform, with an application for approximately €12 million in Polish grant financing under evaluation. CDMO momentum continues with $3.1 million in committed orders and a target of $5 million in 2026 revenue, supported by an expanded clinical manufacturing program for a U.S. biopharmaceutical customer. This strategic shift follows the 1-for-10 ADS ratio change in August and H1 2026 results showing growing CDMO traction. The refocusing reduces near-term R&D commitments but leaves the company reliant on non-dilutive funding and CDMO execution to sustain operations.
At the time of this announcement, SCNI was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $1.85 to $16.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.